Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …

Background COVID-19 vaccine supply shortages are causing concerns about compromised
immunity in some countries as the interval between the first and second dose becomes …

Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the
neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer …

The Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is the leading
target for next-generation vaccines against the disease-causing blood-stage of malaria. …

We describe therapeutic monoclonal antibodies isolated from human volunteers vaccinated
with recombinant adenovirus expressing Ebola virus glycoprotein (EBOV GP) and boosted …

Basigin, or CD147, has been reported as a coreceptor used by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) to invade host cells. Basigin also has a well-established …

Background There is an ongoing global effort to design, manufacture, and clinically assess
vaccines against SARS-CoV-2. Over the course of the ongoing pandemic a number of new …

… Author links open overlay panel Pramila Rijal 1 2 * , Francesca R. Donnellan 3 4 * …

Therapeutic antibodies have broad indications across diverse disease states, such as
oncology, autoimmune diseases, and infectious diseases. New research continues to identify …

The highly conserved and essential Plasmodium falciparum reticulocyte-binding protein
homolog 5 (PfRH5) has emerged as the leading target for vaccines that seek to protect against …